StoxSyngene International vs Poly Medicure: share price & financials comparison
NSE: SYNGENE vs POLYMED · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Syngene International vs Poly Medicure at a glance
Syngene International (SYNGENE) has a market capitalisation of ₹16,846 Cr, against ₹16,342 Cr for Poly Medicure (POLYMED). Over the past year Poly Medicure has returned -18.1%, compared with -36.7% for Syngene International. On valuation, Poly Medicure trades at a lower P/E of 51.3 versus 441.0. Poly Medicure earns a higher return on equity (9.8% vs 0.8%). Syngene International comes out ahead on valuation and financial health. Poly Medicure comes out ahead on size, profitability, growth, momentum and technicals. Across the scored metrics below, Syngene International leads on 4 and Poly Medicure on 13. On StoxGud's 10-point checklist, Syngene International scores 3/10 and Poly Medicure scores 6/10.
| Metric | Syngene International | Poly Medicure |
|---|---|---|
| Size | ||
| Market cap | ₹16,846 Cr | ₹16,342 Cr |
| Revenue (latest FY) | ₹3,739 Cr | ₹1,875 Cr |
| Net profit (latest FY) | ₹0 Cr | ₹322 Cr |
| Valuation | ||
| P/E | 441.0 | 51.3 |
| P/B | 3.47 | 5.00 |
| Dividend yield | 0.30% | 0.22% |
| Profitability | ||
| Return on equity | 0.8% | 9.8% |
| Net profit margin | 1.1% | 14.9% |
| Operating margin | 21.3% | 22.7% |
| Growth | ||
| Revenue growth (YoY) | -8.6% | +30.8% |
| Net profit growth (YoY) | — | +3.6% |
| Revenue CAGR (multi-year) | +11.3% | +19.0% |
| Financial health | ||
| Debt to equity | 0.01 | 0.12 |
| Momentum | ||
| 1-month return | +15.8% | -0.2% |
| 1-year return | -36.7% | -18.1% |
| 3-year CAGR | -16.4% | +5.5% |
| 5-year CAGR | -5.3% | +12.2% |
| 10-year CAGR | +4.3% | +23.6% |
| Distance from 52W high | -37.1% | -21.9% |
| Technicals | ||
| RSI (14) | 60 | 52 |
| Price vs 200-day avg | -1.8% | +4.3% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Syngene International | Poly Medicure |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 3/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Syngene International or Poly Medicure?
Syngene International has a market cap of ₹16,846 Cr and Poly Medicure has a market cap of ₹16,342 Cr as of 06 Nov 2026.
Which has a lower P/E, Syngene International or Poly Medicure?
Poly Medicure has the lower P/E: Syngene International trades at 441.0 and Poly Medicure at 51.3.
Which gave better returns in the last year, Syngene International or Poly Medicure?
Poly Medicure did better: Syngene International returned -36.7% and Poly Medicure returned -18.1% over one year.
Is Syngene International or Poly Medicure a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Syngene International scores 3/10 and Poly Medicure scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.